<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37399380</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>28</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS.</ArticleTitle><Pagination><StartPage>e2302143120</StartPage><MedlinePgn>e2302143120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2302143120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2302143120</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease affecting motor neurons and characterized by microglia-mediated neurotoxic inflammation whose underlying mechanisms remain incompletely understood. In this work, we reveal that MAPK/MAK/MRK overlapping kinase (MOK), with an unknown physiological substrate, displays an immune function by controlling inflammatory and type-I interferon (IFN) responses in microglia which are detrimental to primary motor neurons. Moreover, we uncover the epigenetic reader bromodomain-containing protein 4 (Brd4) as an effector protein regulated by MOK, by promoting Ser<sup>492</sup>-phospho-Brd4 levels. We further demonstrate that MOK regulates Brd4 functions by supporting its binding to cytokine gene promoters, therefore enabling innate immune responses. Remarkably, we show that MOK levels are increased in the ALS spinal cord, particularly in microglial cells, and that administration of a chemical MOK inhibitor to ALS model mice can modulate Ser<sup>492</sup>-phospho-Brd4 levels, suppress microglial activation, and modify the disease course, indicating a pathophysiological role of MOK kinase in ALS and neuroinflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>P&#xe9;rez-Cabello</LastName><ForeName>Jes&#xfa;s A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-8849-5092</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville 41009, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvera-Carrasco</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3450-3004</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville 41009, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Jaime M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-4227-9391</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capilla-Gonz&#xe1;lez</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2020-1662</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armaos</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Human Technologies, Istituto Italiano di Tecnologia, Genova 16152, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Life Nano Science, Istituto Italiano di Tecnologia, Genova 16152, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Lima</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0556-9832</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5223-8596</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville 41009, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Xin Wen</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>The Medical Research Council Toxicology Unit, University of Cambridge, Cambridge CB1 2QR, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal-Lasarte</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lall</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA 90048.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA 90048.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Salvador</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9320-4103</Identifier><AffiliationInfo><Affiliation>Instituto de Neurociencias, Universidad Miguel Hern&#xe1;ndez de Elche-CSIC, Alicante 03550, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyata</LastName><ForeName>Yoshihiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5359-6475</Identifier><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Gian G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0001-7524-6310</Identifier><AffiliationInfo><Affiliation>Center for Human Technologies, Istituto Italiano di Tecnologia, Genova 16152, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Life Nano Science, Istituto Italiano di Tecnologia, Genova 16152, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology and Biotechnologies, University Sapienza Rome, Rome 00185, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawarkar</LastName><ForeName>Ritwick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Medical Research Council Toxicology Unit, University of Cambridge, Cambridge CB1 2QR, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Dom&#xed;nguez</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7524-6310</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3732-4960</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville 41009, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roodveldt</LastName><ForeName>Cintia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4124-8769</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a Molecular y Medicina Regenerativa, Universidad de Sevilla-Consejo Superior de Investigaciones Cient&#xed;ficas, Seville 41092, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville 41009, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486694">Brd4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C498977">Mok protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000092468">Bromodomain Containing Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000092468" MajorTopicYN="Y">Bromodomain Containing Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020928" MajorTopicYN="Y">Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">signaling kinase</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>19</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37399380</ArticleId><ArticleId IdType="pmc">PMC10334760</ArticleId><ArticleId IdType="doi">10.1073/pnas.2302143120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caballero-Hernandez D., et al. , The &#x2018;omics&#x2019; of amyotrophic lateral sclerosis. Trends Mol. Med. 22, 53&#x2013;67 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26691296</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman E. L., et al. , Amyotrophic lateral sclerosis. Lancet 400, 1363&#x2013;1380 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R. M., How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten A. C. M., Phatnani H., Przedborski S., Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 44, 658&#x2013;668 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972039</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B. E., Patani R., The microglial component of amyotrophic lateral sclerosis. Brain 143, 3526&#x2013;3539 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley M. E., Baloh R. H., Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715&#x2013;730 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Troutman T. D., Kofman E., Glass C. K., Exploiting dynamic enhancer landscapes to decode macrophage and microglia phenotypes in health and disease. Mol. Cell 81, 3888&#x2013;3903 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500948</ArticleId><ArticleId IdType="pubmed">34464593</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh H., Ikezu T., Transcriptional and epigenetic regulation of microglia in health and disease. Trends Mol. Med. 25, 96&#x2013;111 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377292</ArticleId><ArticleId IdType="pubmed">30578089</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., et al. , TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., et al. , Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres P., et al. , A motor neuron disease mouse model reveals a non-canonical profile of senescence biomarkers. Dis. Model. Mech. 15, dmm049059 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9459393</ArticleId><ArticleId IdType="pubmed">35916061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A., Gurfinkel Y., Polain N., Lamont W., Lyn Rea S., Molecular mechanisms underlying TDP-43 pathology in cellular and animal models of ALS and FTLD. Int. J. Mol. Sci. 22, 4705 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y.-Z., Ma J., Dou J.-Z., The role of TDP-43 in neurodegenerative disease. Mol. Neurobiol. 59, 4223&#x2013;4241 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35499795</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata Y., Akashi M., Nishida E., Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells 4, 299&#x2013;309 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10421840</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal-Lasarte M. M., Franco J. M., Labrador-Garrido A., Pozo D., Roodveldt C., Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia. FASEB J. 31, 2797&#x2013;2816 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28336525</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekhuis J. R., Verhey K. J., Jansen G., Regulation of cilium length and intraflagellar transport by the RCK-kinases ICK and MOK in renal epithelial cells. PLoS One 9, e108470 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171540</ArticleId><ArticleId IdType="pubmed">25243405</ArticleId></ArticleIdList></Reference><Reference><Citation>Aprile-Garcia F., Tomar P., Hummel B., Khavaran A., Sawarkar R., Nascent-protein ubiquitination is required for heat shock&#x2013;induced gene downregulation in human cells. Nat. Struct. Mol. Biol. 26, 137&#x2013;146 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30723328</ArticleId></ArticleIdList></Reference><Reference><Citation>Garske A. L., Peters U., Cortesi A. T., Perez J. L., Shokat K. M., Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc. Natl. Acad. Sci. U.S.A. 108, 15046&#x2013;15052 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174669</ArticleId><ArticleId IdType="pubmed">21852571</ArticleId></ArticleIdList></Reference><Reference><Citation>Warde-Farley D., et al. , The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38, W214&#x2013;W220 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896186</ArticleId><ArticleId IdType="pubmed">20576703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y., et al. , Brd4 modulates the innate immune response through Mnk2&#x2013;eIF4E pathway-dependent translational control of I&#x3ba;B&#x3b1;. Proc. Natl. Acad. Sci. U.S.A. 114, E3993&#x2013;E4001 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441817</ArticleId><ArticleId IdType="pubmed">28461486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., et al. , (+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NF&#x3ba;B signaling. Cell Biosci 8, 60 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6245926</ArticleId><ArticleId IdType="pubmed">30479742</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMars K. M., Yang C., Castro-Rivera C. I., Candelario-Jalil E., Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia. Biochem. Biophys. Res. Commun. 497, 410&#x2013;415 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29448097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., et al. , TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp. Neurol. 273, 24&#x2013;35 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V., et al. , The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia 68, 407&#x2013;421 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata Y., Ikawa Y., Shibuya M., Nishida E., Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. J. Biol. Chem. 276, 21841&#x2013;21848 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Yang C., Candelario-Jalil E., Role of BET proteins in inflammation and CNS diseases. Front. Mol. Biosci. 16, 748449 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481655</ArticleId><ArticleId IdType="pubmed">34604312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Wu R., Tang D., Kang R., The BET family in immunity and disease. Signal Transduct. Target. Ther. 6, 23 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813845</ArticleId><ArticleId IdType="pubmed">33462181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K. H., et al. , RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells. J. Neuroinflamm. 12, 12&#x2013;18 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359438</ArticleId><ArticleId IdType="pubmed">25890327</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb E., Herre M., Zucker-Scharff I., Darnell R. B., Allis C. D., BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice. Nat. Neurosci. 18, 1464&#x2013;1473 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752120</ArticleId><ArticleId IdType="pubmed">26301327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S. Y., Lee A. Y., Lai H. T., Zhang H., Chiang C. M., Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843&#x2013;857 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595396</ArticleId><ArticleId IdType="pubmed">23317504</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkina B. S., Nikolajczyk G. V., Dennis A. C., Macrophage inflammatory responses BET inhibitor JQ1 impair mouse inflammation: Brd2 genetic disruption and BET protein function is required for. J. Immunol. 190, 3670&#x2013;3678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608815</ArticleId><ArticleId IdType="pubmed">23420887</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan Y. M., Kirkham P., Barnes P. J., Adcock I. M., Brd4 Is essential for IL-1b-induced inflammation in human airway epithelial cells. PLoS One 9, e95051 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997389</ArticleId><ArticleId IdType="pubmed">24759736</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik N., et al. , Suppression of interferon &#x3b2; gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem. J. 468, 363&#x2013;372 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613535</ArticleId><ArticleId IdType="pubmed">25891802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Wu D., Moskaluk C. A., Fu Z., Distinct expression patterns of ICK/MAK/MOK protein kinases in the intestine implicate functional diversity. PLoS One 8, e79359 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820702</ArticleId><ArticleId IdType="pubmed">24244486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N. J., Miller T. M., Baloh R. H., TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 18809&#x2013;18814 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gois A. M., Mendon&#xe7;a D. M. F., Freire M. A. M., Santos J. R., In vitro and in vivo models of amyotrophic lateral sclerosis: An updated overview. Brain Res. Bull. 159, 32&#x2013;43 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32247802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V. V, et al., The Loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 106, 789&#x2013;805.e5 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., et al. , The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X., Vocadlo D., Krieger C., Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. Neurosci. Lett. 458, 70&#x2013;74 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19379791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M., Lee K.-W., Choi S.-M., Yang E. J., TDP-43 modification in the hSOD1G93A amyotrophic lateral sclerosis mouse model. Neurol. Res. 37, 253&#x2013;262 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25213598</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M., et al. , Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol. Aging 36, 492&#x2013;504 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25085783</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., et al. , Targeting extracellular cyclophilin A reduces neuroinflammation and extends survival in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 37, 1413&#x2013;1427 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S.-G., et al. , Pathological Modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol. Neurobiol. 56, 2007&#x2013;2021 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock R. B., et al. , Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 17, 942&#x2013;964 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC523558</ArticleId><ArticleId IdType="pubmed">15489356</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J. P., et al. , Interferon-&#x3b2; plays a detrimental role in experimental traumatic brain injury by enhancing neuroinflammation that frives chronic neurodegeneration. Neurobiol. Dis. 40, 2357&#x2013;2370 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083281</ArticleId><ArticleId IdType="pubmed">32029532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-H., et al. , TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 183, 636&#x2013;649.e18 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan P.-H., Ji J., Hsing C.-H., Tan R., Ji R.-R., Emerging roles of type-I interferons in neuroinflammation, neurological diseases, and long-haul COVID. Int. J. Mol. Sci. 23, 14394 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9696119</ArticleId><ArticleId IdType="pubmed">36430870</ArticleId></ArticleIdList></Reference><Reference><Citation>Pong Ng H., et al. , CITED2 limits pathogenic inflammatory gene programs in myeloid cells. FASEB J. 34, 12100&#x2013;12113 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496281</ArticleId><ArticleId IdType="pubmed">32697413</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., et al. , Action by CITED2 in the nucleus B &#x3ba; negative feedback regulation of NF. J. Immunol. 186, 539&#x2013;548 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21098220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gun-Dong K., et al. , CITED2 restrains proinflammatory macrophage activation and response. Mol. Cell. Biol. 38, e00452-17 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5809687</ArticleId><ArticleId IdType="pubmed">29203644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T., et al. , Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat. Commun. 10, 4353 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6761150</ArticleId><ArticleId IdType="pubmed">31554795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanmarco L. M., et al. , Identification of environmental factors that promote intestinal inflammation. Nature 611, 801&#x2013;809 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9898826</ArticleId><ArticleId IdType="pubmed">36266581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffell D., et al. , A CREB-C/EBP&#x3b2; cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. U.S.A. 106, 17475&#x2013;17480 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762675</ArticleId><ArticleId IdType="pubmed">19805133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkin D. M., et al. , C/EBP&#x3b2; regulates the M2 transcriptome in &#x3b2;-adrenergic-stimulated macrophages. Brain. Behav. Immun. 80, 839&#x2013;848 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660400</ArticleId><ArticleId IdType="pubmed">31132458</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., et al. , Peli1 impairs microglial A&#x3b2; phagocytosis through promoting C/EBP&#x3b2; degradation. PLOS Biol. 18, e3000837 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561136</ArticleId><ArticleId IdType="pubmed">33017390</ArticleId></ArticleIdList></Reference><Reference><Citation>Muromoto R., et al. , Regulation of NFKBIZ gene promoter activity by STAT3, C/EBP&#x3b2;, and STAT1. Biochem. Biophys. Res. Commun. 613, 61&#x2013;66 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35537286</ArticleId></ArticleIdList></Reference><Reference><Citation>Annemann M., et al. , Atypical I&#x3ba;B proteins in immune cell differentiation and function. Immunol. Lett. 171, 26&#x2013;35 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26804211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Brain-protective mechanisms of transcription factor NRF2: Toward a common strategy for neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 62, 255&#x2013;277 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34637322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen T. H., IRF and STAT transcription factors&#x2013;From basic biology to roles in infection, protective immunity, and primary immunodeficiencies. Front. Immunol. 1, 3047 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331453</ArticleId><ArticleId IdType="pubmed">30671054</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy E. R., et al. , Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid &#x3b2; plaques. Immunity 55, 879&#x2013;894.e6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109419</ArticleId><ArticleId IdType="pubmed">35443157</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue F., Tian J., Yu C., Du H., Guo L., Type I interferon response-related microglial Mef2c deregulation at the onset of Alzheimer&#x2019;s pathology in 5&#xd7;FAD mice. Neurobiol. Dis. 152, 105272 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7956132</ArticleId><ArticleId IdType="pubmed">33540048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez S., et al. , Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Sci. Transl. Med. 13, eaaz4699 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779652</ArticleId><ArticleId IdType="pubmed">34233951</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J. P., et al. , Traumatic brain injury induces cGAS activation and type I interferon signaling in aged mice. Front. Immunol. 12, 710608 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423402</ArticleId><ArticleId IdType="pubmed">34504493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazmi A., et al. , Chronic neurodegeneration induces type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression. Glia 67, 1254&#x2013;1276 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520218</ArticleId><ArticleId IdType="pubmed">30680794</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman B. A., et al. , Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Main B. S., et al. , Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson&#x2019;s disease. Glia 64, 1590&#x2013;604 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27404846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Yang B. O., Zhang D., Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia 59, 946&#x2013;58 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar A., Ng H. P., Kim G. D., Chan E. R., Mahabeleshwar G. H., BHLHE40 promotes macrophage pro-inflammatory gene expression and functions. FASEB J. 35, 21940 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607355</ArticleId><ArticleId IdType="pubmed">34551158</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook M. E., Jarjour N. N., Lin C. C., Edelson B. T., Transcription factor Bhlhe40 in immunity and autoimmunity. Trends Immunol. 41, 1023&#x2013;1036 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606821</ArticleId><ArticleId IdType="pubmed">33039338</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., et al. , Bromodomain containing protein 4 (BRD4) regulates expression of its interacting coactivators in the innate response to respiratory syncytial virus expression of host defense mechanisms and remodeling genes through changes in promoter accessibility. Front. Mol. Biosci. 8, 728661 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577543</ArticleId><ArticleId IdType="pubmed">34765643</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A., Nativio R., Berger S. L., Bonini N. M., Epigenetic regulation in neurodegenerative diseases. Trends Neurosci. 41, 587&#x2013;598 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6174532</ArticleId><ArticleId IdType="pubmed">29885742</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Pacheco A., et al. , Epigenetic mechanisms of gene regulation in amyotrophic lateral sclerosis. Adv. Exp. Med. Biol. 978, 255&#x2013;275 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28523551</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., et al. , Genetic and environmental effects on gene expression signatures of blood pressure: A transcriptome-wide twin study. Hypertension 71, 457&#x2013;464 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877117</ArticleId><ArticleId IdType="pubmed">29311254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopic M., et al. , Downregulation of mapk/mak/mrk overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus. J. Med. Biochem. 41, 282&#x2013;289 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9375534</ArticleId><ArticleId IdType="pubmed">36042901</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Garc&#xed;a R., Mart&#xed;n-Herrero L., Blanca-Pariente L., P&#xe9;rez-Cabello J., Roodveldt C., Immune signaling kinases in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Int. J. Mol. Sci. 22, 13280 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8707599</ArticleId><ArticleId IdType="pubmed">34948077</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Vandoorne T., Steyaert J., Staats K. A., Van Den Bosch L., The multifaceted role of kinases in amyotrophic lateral sclerosis: Genetic, pathological and therapeutic implications. Brain 143, 1651&#x2013;1673 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296858</ArticleId><ArticleId IdType="pubmed">32206784</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M. E., et al. , Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772&#x2013;1775 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitini C., Conti S., Perni M., Guidi F., Cascella R., TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLoS One 9, 86720 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907574</ArticleId><ArticleId IdType="pubmed">24497973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R., et al. , Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies. J. Biol. Chem. 291, 19437&#x2013;19448 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Roodveldt C., Yap X. W., Sawarkar R., SLAM-Seq analysis of early transcriptional changes by C13 MOK-inhibitor in microglial cells exposed to TDP-43-aggregates. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE233569. Deposited 26 May 2023.</Citation></Reference><Reference><Citation>Roodveldt C., Franco J. M., G&#xf3;mez-Lima M., Effect of C13 MOK-inhibitor on LPS-induced responses in primary microglial cells. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE233719. Deposited 30 May 2023.</Citation></Reference><Reference><Citation>Roodveldt C., Pozo D., Effect of MOK in LPS-induced responses in microglial cells. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234160. Deposited 5 June 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>